Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 5/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | MLNR | O43193 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL70796 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP2C19HSD17B10CLK4CTSL | |
| Hydrochloric Acid SCHEMBL382110 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP2C19HSD17B10CLK4CTSL | |
| SCHEMBL21460253 | 0.91 | DRD2 (0.49) | CYP1A2CYP2C19HSD17B10CLK4CTSL | |
| SCHEMBL5478814 | 0.87 | KMT2A (0.50) | CTSLCTSSCTSKMLNRCYP3A4 | |
| SCHEMBL18855742 | 0.87 | KMT2A (0.54) | CTSLCTSSCTSKKMT2ADRD2 | |
| SCHEMBL3474592 | 0.85 | TSHR (0.55) | CTSLCTSSCTSKKMT2ATSHR | |
| SCHEMBL3128888 | 0.83 | KMT2A (0.44) | CYP1A2CYP2C19HSD17B10CLK4MLNR | |
| SCHEMBL14492926 | 0.80 | POLB (0.49) | MLNRCYP3A4KMT2ADRD2DRD3 | |
| SCHEMBL377685 | 0.80 | CTSS (0.48) | CYP1A2CYP2C19HSD17B10CLK4CTSL | |
| SCHEMBL4069931 | 0.78 | DDB1 (0.48) | CTSLCTSBCTSSCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| CN-101258143-B | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-2441763-A1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | Glaxo Group Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| EP-2029538-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| CN-101258143-A | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | CN | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| EP-1902022-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007144400-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144400-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007007018-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | CYP1A2 299/4885CYP2C19 527/4885HSD17B10 1399/4885 |
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | CYP1A2 634/4885CYP2C19 913/4885HSD17B10 3350/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | CYP1A2 444/4885CYP2C19 626/4885HSD17B10 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.